MDNA : Medicenna Therapeutics Corp Stock Profile
Last Updated:
Medicenna Therapeutics Corp trades with the ticker MDNA on the TSX and is in the Biotechnology industry.
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield
Overview
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
MDNA.TO Stock Price and Key Stats
MDNA Stock Key Stats
Exchange: TSX
Market Cap : $158.98MM
PE Ratio:
Price: (Updated: )
Medicenna Therapeutics Corp (MDNA) vs Competitors in Biotechnology
Lets see how MDNA.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:Aeterna Zentaris Inc, Aptose Biosciences Inc, BELLUS Health Inc, Fennec Pharmaceuticals Inc, IMV Inc
.Biotechnology Industry Comparisons
| Company | Market Cap ($MM) | P/E Ratio | EV/EBITDA | Dividend Yield |
|---|---|---|---|---|
| Aeterna Zentaris Inc (AEZS) | $25.381 | N/A | 4.569 | N/A% |
| Aptose Biosciences Inc (APS) | $9.779 | N/A | 0.068 | N/A% |
| BELLUS Health Inc (BLU) | $2,470.298 | N/A | -16.428 | 0.0% |
| Fennec Pharmaceuticals Inc (FRX) | $197.023 | 72.0 | 19.905 | N/A% |
| IMV Inc (IMV) | $13.117 | N/A | -0.843 | 0.0% |
Comparisons within Biotechnology
- Medicenna Therapeutics Corp (MDNA) vs Aeterna Zentaris Inc (AEZS)
- MDNA has higher EPS (-0.38 vs -3.18). AEZS and MDNA both have P/E’s under 0.
- Medicenna Therapeutics Corp (MDNA) vs Aptose Biosciences Inc (APS)
- MDNA has higher EPS (-0.38 vs -5.76). APS and MDNA both have P/E’s under 0.
- Medicenna Therapeutics Corp (MDNA) vs BELLUS Health Inc (BLU)
- MDNA has higher EPS (-0.38 vs -0.96). BLU provides dividends, while MDNA does not. BLU and MDNA both have P/E’s under 0.
- Medicenna Therapeutics Corp (MDNA) vs Fennec Pharmaceuticals Inc (FRX)
- FRX has higher EPS (0.1 vs -0.38). MDNA has a P/E under 0, indicating FRX (P/E 72.0) is in a better position.
- Medicenna Therapeutics Corp (MDNA) vs IMV Inc (IMV)
- MDNA has higher EPS (-0.38 vs -6.11). IMV provides dividends, while MDNA does not. IMV and MDNA both have P/E’s under 0.
Our Recommendation: Hold
Features a lower EV/EBITDA ratio (-6.11) than the industry average (1.16), indicating attractive valuation.
How to Buy MDNA stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:| Image | Product Title | Features | Price |
|---|---|---|---|
Editor's Choice  |
| Get $25 Signup Bonus | |
Reliable Pick  |
| Get $50 Free Stock Trades |